Arctic Bioscience - Invitation to presentation of Q3 operational update and HeROPA-analyses results

07 Nov 2025 08:00 CET

Arctic Bioscience will publish its Q3 2025 operational update on Monday 10[th]
of November, at 07:00 CET.

The same day at 10:00 CET, the Company will host a webcast to present the
operational update and also results from the HeROPA-trial analysis. Following
the presentation, it will be opened for questions from the audience.

Webcast details:

Date: Monday 10[th] of November 2025

Time: 10:00 CET

Format: Webcast and Q&A

Language: Norwegian/English

The presentation can be accessed with the link below:

https://events.teams.microsoft.com/event/a5afa4c4-2a3b-40e4-9137
-9c1d28c69aee@ce618813-5158-40b5-b6d0-2f2cd3f39b20

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

For more information, please contact:

Christer L. Valderhaug

CEO

Mobile: +47 920 84 601

E-mail: christer@arctic-bioscience.com

Jone R. Slinning

CFO

Mobile: +47 948 75 469

E-mail: jone@arctic-bioscience.com

About Arctic Bioscience

Arctic Bioscience is a biotech company developing and commercializing
pharmaceutical and nutraceutical products based on unique bioactive marine
compounds.

The company is developing HRO350 - a novel oral drug candidate. HRO350 is being
developed for treatment of patients with mild-to-moderate psoriasis. This is a
large patient group in need of new effective medicines with beneficial safety
profile.

Nutraceuticals from Arctic Bioscience are sold globally as bulk ingredients as
well as finished goods under the ROMEGA® brand.

Arctic Bioscience is led by a highly skilled team of talents with diverse and
highly relevant background.

More information:
Access the news on Oslo Bors NewsWeb site